Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model

Cisplatin is the most effective and widely used chemo-therapeutic agent for many types of cancer. Unfortunately, its clinical use is limited by its adverse effects, notably bone marrow suppression leading to abnormal hematopoiesis. We previously revealed that neuropeptide Y (NPY) is responsible for...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Min Hee, Jung, In Kyung, Min, Woo-Kie, Choi, Jin Ho, Kim, Gyu Man, Jin, Hee Kyung, Bae, Jae-sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595171/
https://www.ncbi.nlm.nih.gov/pubmed/28712386
http://dx.doi.org/10.5483/BMBRep.2017.50.8.099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595171/
https://www.ncbi.nlm.nih.gov/pubmed/28712386
http://dx.doi.org/10.5483/BMBRep.2017.50.8.099

Ejemplares similares